Amir Boloor Is Appointed Board Chair of Convalon: Impressive Track Record in Accelerating Growth

November 13, 2020

Amir Boloor, President of  Caspian Equity Partners, Inc., has been appointed as Chair of the Company’s Board of Directors.

Amir Boloor, an independent director of the Company, is also Chair of the Company’s recently announced Special Committee, appointed to explore and evaluate a range of strategic alternatives available to the Company in order to enhance shareholder value.

Abe Schwartz, former Chair of the Board said, “I am delighted that Amir has accepted the appointment as Chair of the Board during a time where the Company is undertaking a strategic review process in order to ensure that all available alternatives to enhance value for our shareholders are being evaluated. Amir has earned the respect of his colleagues on the Board.”  Mr. Schwartz, the largest shareholder of the Company, is continuing as an active member of the Board.

“Amir has an impressive track record in accelerating growth and creating shareholder value as an investor and capital markets leader,” said Brian Pedlar, President and CEO of Covalon. “We are delighted to have Amir assume the role of Chair.”

Amir Boloor, an independent director of the Company, is the President of Caspian Equity Partners, Inc., a Vancouver, British Columbia private investment firm he founded in 2012. He has specialized in helping entrepreneurs accelerate growth and optimize performance while propelling long-term profitability and value. Prior to founding Caspian Equity Partners, Inc., Mr. Boloor held various positions in the Mergers & Acquisitions and Diversified Investment Banking groups of TD Securities, Inc. where he advised Boards and executive teams of mid-market and large-cap companies on numerous strategic review mandates, initial public offerings, mergers, acquisitions, divestitures, corporate restructures, leveraged buyouts, and takeover defenses. Mr. Boloor has a Bachelor of Commerce with Honours Finance from the University of British Columbia. Mr. Boloor is a Chartered Financial Analyst from the CFA Institute.

Source Convalon

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”